Search
Dexamethasone Treatment Options
A collection of 1446 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.
793 - 804 of 1446
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
INtravitreal and Aqueous Dexamethasone Levels After DEXtenza
Unknown
A prospective, open-label, interventional study to determine intraocular concentration levels of dexamethasone following use of the DEXTENZA® implant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2021
Locations: California Retina Consultants, Paso Robles, California +2 locations
Conditions: Ocular Disease Requiring Surgery
Intraoperative Dexamethasone and Its Effect on Hyperglycemia
Withdrawn
To study the effect of intra-operative dexamethasone on the management of post-operative blood sugar in diabetic patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/19/2021
Locations: Genesys Regional Medical Center, Grand Blanc, Michigan
Conditions: Diabetes Mellitus
Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Completed
This phase Ib trial studies the side effects and best doses of carfilzomib and bendamustine hydrochloride when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as bendamustine hydrochloride, work to stop the growth of cancer cells by killing the cells. Biological therapies, such as... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2021
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
Terminated
The primary objective was to describe the safety profile of carfilzomib plus dexamethasone regimen in adults with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy at study entry.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/14/2020
Locations: Research Site, Palm Springs, California +30 locations
Conditions: Relapsed or Refractory Multiple Myeloma
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
Completed
This is a Phase I-Ib/II, open-label, multicenter study of AUY922 administered intravenously in patients with multiple myeloma to determine the maximum tolerated dose. The Phase II part will investigate the efficacy of AUY922 in patients with multiple myeloma. Additionally, the study includes a Phase Ib combination part of AUY922 administered in combination with bortezomib, to determine the maximum tolerated dose of the combination drugs in patients with multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2020
Locations: Mayo Clinic - Arizona Cancer Clinical Research Unit, Scottsdale, Arizona +8 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Completed
The study will evaluate the effects of BHQ880 in patients with previously untreated multiple myeloma and renal insufficiency who are not considered candidates for bisphosphonate therapy. The primary objective of the study will be to evaluate the effect of BHQ880 in combination with bortezomib and dexamethasone, compared to placebo administered with the combination on the time to first Skeletal Related Event (SRE) on study.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
12/11/2020
Locations: University Chicago Hospital Dept. of Univ of Chicago (2), Chicago, Illinois +7 locations
Conditions: Multiple Myeloma, Renal Insufficiency
A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%
Completed
This is a post-approval, open-label, randomized, self-controlled prospective clinical study to evaluate the safety and ocular efficacy of Dexycu in controlling postoperative ocular pain and inflammation associated with cataract surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2020
Locations: Harvard Eye Associates, Laguna Hills, California +1 locations
Conditions: Cataract
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
Completed
The goal of this clinical research study is to learn if intensive chemotherapy (with monoclonal antibody therapy in some patients) given for 8 courses over 5 to 6 months followed by monthly maintenance chemotherapy for 2 ½ years can improve or cure acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma.
Gender:
ALL
Ages:
All
Trial Updated:
12/01/2020
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, Acute Lymphoblastic Leukemia
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
Completed
The purpose of this study is to test the safety of a combination of study drugs called selinexor (KPT-330) and ixazomib (MLN9708) with a low dose of dexamethasone. This study tests different doses of the study drug, selinexor to see which dose is safer in people. Depending on which group (dose level) you are in, the dose of selinexor will vary, but the ixazomib and dexamethasone doses will be the same among the groups.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/23/2020
Locations: Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +6 locations
Conditions: Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
Completed
The purpose of this research study is to find the maximum tolerated dose of a drug called romidepsin when given with a treatment regimen called GemOxD. GemOxD is a routine treatment for certain types of lymphoma, and involves the administration of three drugs: gemcitabine, oxaliplatin, and dexamethasone. In addition to finding the maximum tolerated dose of romidepsin, the investigators want to look at the side effects of these drugs when given together, as well as how the lymphoma responds to th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2020
Locations: University of Chicago, Chicago, Illinois +1 locations
Conditions: Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse
TPI Medication Comparison - Ketorolac, Lidocaine, or Dexamethasone
Terminated
Hypothesis
The main hypothesis of this study is that anti-inflammatory medications (ketorolac or dexamethasone) will provide longer-lasting and greater pain relief than just lidocaine in trigger point injections where a local twitch response is evoked at the time of the injection.
Purpose/Specific Aims
The primary objective of this study is to compare the efficacy of three substances used in TPIs with a LTR identified at the time of the injection: a CS (dexamethasone), a NSAID (ketorolac), or... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
11/11/2020
Locations: University of Utah Orthopaedic Center, Salt Lake City, Utah
Conditions: Myofascial Pain
Single Shot Liposomal Bupivicaine in Rotator Cuff Surgery
Completed
This document is a protocol for a human research study. This study is to be conducted according to United States standards of Good Clinical Practice in accordance with applicable Federal regulations and institutional research policies and procedures.
Liposomal bupivacaine (LB) has been shown to decrease post-operative pain and narcotic use when administered perioperatively as a local injection during arthroplasty procedures. Studies have also demonstrated that LB used in conjunction with dexame... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/09/2020
Locations: American Health Network, Avon, Indiana
Conditions: Rotator Cuff Tear, Pain, Postoperative
793 - 804 of 1446